RESUMEN
@#Most of the infected patients completely recovered after covid-19 infection. However, a substantial proportion of patients who have been infected with SARS-CoV-2 continue to have symptoms long past the time that they recovered from the initial phases of covid-19 disease. At NICE guideline, </br> 1. Acute covid-19: signs and symptoms of covid-19 for up to 4 weeks, </br> 2. Ongoing symptomatic covid-19: signs and symptoms of covid-19 from 4 to 12 weeks, </br> 3. Post-covid-19 syndrome: signs and symptoms that develop during or after an infection consistent with covid-19, continue for more than 12 weeks and are not explained by an alternative diagnosis. </br> In addition to the clinical case definitions, ‘long covid’ is commonly used to describe signs and symptoms that continue or develop after acute covid-19. As the pandemic of covid-19 continues, numerous additional symptoms, such as fever, dry cough, shortness of breath, fatigue, myalgias, vomiting or diarrhea, headache and weakness. Other critical and severe complications of covid-19 can include impaired function of the heart, brain, lung, liver, kidney, and coagulation system. Early reports have now emerged on post-acute infectious consequences of covid-19, with studies from the United States, Europe and China reporting outcomes for those who survived hospitalization for acute covid-19. An observational cohort study from 38 hospitals in Michigan, United States evaluated the outcomes of 1,250 patients discharged alive at 60 day. Of 488 patients who completed the telephone survey in this study, 32.6% of patients reported persistent symptoms. Dyspnea while walking up the stairs 22.9% was most commonly reported, while other symptoms included cough 15.4% and persistent loss of taste/smell 13.1%. Post-hospital discharge care of COVID-19 survivors has been recognized as a major research priority by professional organizations.
RESUMEN
Myoglobin acts as an oxygen store and a reactive oxygen species acceptor in muscles. We examined myoglobin mRNA in rat cardiac ventricle and skeletal muscles during the first 42 days of life and the impact of transient neonatal hypo- and hyperthyroidism on the myoglobin gene expression pattern. Cardiac ventricle and skeletal muscles of Wistar rats at 7-42 days of life were quickly removed, and myoglobin mRNA was determined by Northern blot analysis. Rats were treated with propylthiouracil (5-10 mg/100 g) and triiodothyronine (0.5-50 µg/100 g) for 5, 15, or 30 days after birth to induce hypo- and hyperthyroidism and euthanized either just after treatment or at 90 days. During postnatal (P) days 7-28, the ventricle myoglobin mRNA remained unchanged, but it gradually increased in skeletal muscle (12-fold). Triiodothyronine treatment, from days P0-P5, increased the skeletal muscle myoglobin mRNA 1.5- to 4.5-fold; a 2.5-fold increase was observed in ventricle muscle, but only when triiodothyronine treatment was extended to day P15. Conversely, hypothyroidism at P5 markedly decreased (60%) ventricular myoglobin mRNA. Moreover, transient hyperthyroidism in the neonatal period increased ventricle myoglobin mRNA (2-fold), and decreased heart rate (5%), fast muscle myoglobin mRNA (30%) and body weight (20%) in adulthood. Transient hypothyroidism in the neonatal period also permanently decreased fast muscle myoglobin mRNA (30%) and body weight (14%). These results indicated that changes in triiodothyronine supply in the neonatal period alter the myoglobin expression program in ventricle and skeletal muscle, leading to specific physiological repercussions and alterations in other parameters in adulthood.